Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis : A Model-Based Meta-Analysis by Checchio, T. et al.
Quantitative Evaluations of Time-Course and
Treatment Effects of Systemic Agents for
Psoriasis: A Model-Based Meta-Analysis
T Checchio1, S Ahadieh1, P Gupta1, J Mandema2, L Puig3, R Wolk1, H Valdez4, H Tan1,
S Krishnaswami1, A Tallman4, M Kaur5 and K Ito1
Aggregate data model-based meta-analysis is a regression approach to compare the dose–response and/or time-course
across different treatments using summary level data from the literature. Literature search and systematic review following
the Cochrane approach yielded 912 sources for investigational and approved treatments for psoriasis. In addition, data for
tofacitinib were obtained from an internal database. Tofacitinib is an oral Janus kinase inhibitor. Two mathematical models
were developed for Psoriasis Area and Severity Index (PASI) response in moderate to severe psoriasis patients to quantify
the time to maximum effect for PASI75 and to evaluate the dose–response relationship for PASI responders (PASI50,
PASI75, PASI90, PASI100) at Week 12. Body weight exhibited an inverse effect on the placebo component of both models,
suggesting that body weight affects the overall PASI response regardless of drug. This analysis provides a quantitative
framework for efficacy comparisons across psoriasis treatments.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Treatment options for patients with moderate to severe pso-
riasis include oral and injectable/infusible systemic medication.
However, quantitative comparison for the treatment effect
across drugs remains unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Two mathematical models were developed for Psoriasis Area
and Severity Index response to evaluate the magnitude of effect
and the onset of the effect (time course of the treatment) for
each drug. The impact of body weight (covariate) was also
tested.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 This analysis furthered the understanding of psoriatic treat-
ments by providing a framework for efﬁcacy comparisons across
systemic drugs. It also suggests that decisions to increase the
dose may be particularly beneﬁcial to heavier patients if they
fail to show meaningful responses at lower doses.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 This model-based meta-analysis based on a systematic litera-
ture review provides a quantitative understanding of pharmaco-
dynamics across drugs and may allow better dose selections.
Psoriasis is a common chronic skin disorder typically character-
ized by erythematous papules and plaques with a silver scale,
although other clinical presentations also occur.1 Management of
psoriasis may involve topical and systemic medications, photo-
therapy, stress reduction, climatotherapy, and various adjuncts
based on individual patients’ clinical situations.2
Aggregate data (study-level) model-based meta-analysis is a
regression approach to compare the dose–response and/or time-
course across different treatments by using data from the literature.
As more drugs become available to treat patients, the compilation
of clinical responses across drugs provides a better understanding
of whether newer agents offer greater pharmacological beneﬁt
compared with existing ones, including faster onset of action,
increased efﬁcacy, and/or better safety proﬁles.
In this analysis, data from the literature on Psoriasis Area and
Severity Index (PASI) response in patients with moderate to severe
psoriasis were collected for both investigational and marketed
drugs. Data for tofacitinib were obtained from an internal Pﬁzer
database (all tofacitinib studies used in this analysis have been pub-
lished). Tofacitinib is an oral Janus kinase (JAK) inhibitor. An oral
tablet of tofacitinib dosed as 5mg or 10mg twice daily (b.i.d.) was
demonstrated to be efﬁcacious for the treatment of moderate to
severe psoriasis in four phase III clinical studies.3–5
To evaluate the magnitude and onset of the drug effect, two
mathematical models were developed: 1) a longitudinal model to
quantify the time course of PASI75 (primary clinical endpoint
representing the proportion of patients achieving 75%
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reduction in PASI score from baseline), and 2) a landmark model
to quantify the dose–response relationship for PASI responders
(PASI50, PASI75, PASI90, PASI100) at Week 12 (primary efﬁ-
cacy timepoint in the majority of studies; primary efﬁcacy time-
points ranged from 10–24 weeks across all studies). The impact
of body weight was tested in both models. The results from the
two models were compared, and the predictive performance for
PASI response was assessed. This analysis allows a quantitative
understanding of treatment options for patients with psoriasis by
providing a framework for efﬁcacy comparisons across systemic
agents.
RESULTS
Available data
The literature search yielded 912 abstracts, of which 151 studies
were identiﬁed for potential inclusion in the analyses. Following
application of additional inclusion/exclusion criteria, the ﬁnal
analysis included 71 studies for landmark and 57 studies for lon-
gitudinal analyses (Figure 1; Supplementary Material).
The ﬁnal database included interleukin (IL)-12/23 inhibitors
(ustekinumab, briakinumab), tumor necrosis factor (TNF)-a
inhibitors (adalimumab, etanercept, certolizumab, inﬂiximab),
IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), T-
lymphocyte (CD2) antagonist (alefacept), phosphodiesterase-4
(PDE4) inhibitor (apremilast), JAK inhibitors (tofacitinib, barici-
tinib), and traditional oral agents (methotrexate, cyclosporine,
acitretin). All drugs were included in the landmark model; how-
ever, the longitudinal model did not include cyclosporine, acitre-
tin, or baricitinib due to insufﬁcient longitudinal data.
Longitudinal model
The temporal relationship between dose and PASI75 response
was adequately described by the longitudinal model. PASI75
response increased toward a maximum that eventually plateaued
over time for most treatments. The PASI75 time course curves
for the model-predicted PASI75 were overlaid with the observed
data for each drug (Figure 2).
ET50 and ET90 (the time to reach 50% and 90% of the maxi-
mal treatment effect (Emax)) were estimated from the model
(Table 1). Emax was achieved by Week 12 for the majority of
drugs except alefacept (estimated ET50 for alefacept was 11.1
weeks; ET90 was not able to be estimated from available data).
The mean (standard deviation (SD)) ET50 across all drugs was
6.48 (2.06) weeks, and ranged from 3.7–9.2 weeks, with the
exception of alefacept (Table 1; Figure 2). The mean (SD) ET90
across all drugs, excluding alefacept, was 12.6 (2.92) weeks. A
trend between ET50 and Emax was detected, such that drugs with
higher Emax tended to have a shorter ET50 than those with lower
Figure 1 Search strategy flow diagram. Details of studies included in the final database are listed in the Supplementary Appendix. PASI75,75%
reduction from baseline Psoriasis Area and Severity Index score.
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Emax. For example, the IL-17 inhibitors were predicted to achieve
ET50 following 4 weeks of treatment. Correspondingly, the
predicted PASI75 response for IL-17 inhibitors ranged from 22–
49% at 4 weeks and reached 80% at 12 weeks. In contrast, other
systemic agents with longer ET50, such as methotrexate and alefa-
cept, had lower PASI75 responses (less than 30% at 12 weeks).
Figure 2 Time-course of PASI75 response in the longitudinal model: predicted vs observed PASI75 response by drug. Placebo time course is based on
results from studies including both injectable/infusible and oral agents. Lines are model prediction for average body weight 90 kg subjects. Circles repre-
sent observed data, with size proportional to the N of patients in the study arm. PASI75,75% reduction from baseline Psoriasis Area and Severity Index
score. [Color figure can be viewed at cpt-journal.com]
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Treatment effect was well-characterized by an Emax model with
a different Emax and potency (ED50; dose achieving 50% of maxi-
mal response) for each drug within each class. Body weight was
shown to have an inverse relationship with both the placebo
response (B) and the rate constant of drug effect (kdrug), in which
the rate constant describes the time-course component in the
model. The median body weight effect estimates (95% conﬁdence
interval) in the ﬁnal model for the maximal placebo effect and
the rate constant of drug effect were –0.193 [–0.277, –0.119]
and –0.867 [–1.32, –0.496], respectively (from nonparametric
bootstrap; N5 1,000); both excluded 0. The ﬁnal parameter esti-
mates for the longitudinal model are presented in Supplemen-
tary Table 1.
Landmark model
Dose–response for PASI endpoints (PASI50, 75, 90, and 100)
was well characterized by a sigmoidal Emax function with a differ-
ent Emax for each drug class and different ED50 for every drug
within each class. The ﬁnal parameter estimates for the landmark
model are presented in Supplementary Table 2. The dose–
Table 1 Longitudinal model-predicted percentage of PASI75 responders for systemic treatment in patients with moderate to severe
psoriasis at 4 and 12 weeks
Drug Clinical dose ET50 (Week) ET90 (Week)
PASI75 (%)
Week 4 Week 12
TNF-a inhibitor
Adalimumab 40mg Q2W 6.0 (4.6, 7.8) 11.7 (8.5, 16.1) 15.6 (5.15, 30.2) 65.9 (53.6, 76.8)
Certolizumaba 200mg Q2W 4.2 (2.8, 6.0) 9.9 (6.5, 14.3) 38.8 (21.7, 59.4) 74.5 (62.2, 84.1)
Etanercept 25mg BIW 8.2 (6.3, 10.8) 16.4 (12.3, 20.8) 4.64 (0.00, 10.7) 32.0 (20.7, 44.0)
Etanercept 50mg BIW 7.7 (6.1, 9.9) 14.6 (11.8, 19.0) 6.87 (1.08, 15.7) 48.7 (34.2, 60.6)
Infliximab 5mg/kg Q8W 4.7 (3.5, 6.2) 10.0 (6.8, 14.2) 32.7 (16.0, 51.5) 75.3 (62.6, 85.8)
IL-17 inhibitor
Brodalumaba 210mg Q2W 3.9 (2.8, 5.3) 9.2 (6.1, 13.1) 46.9 (27.1, 66.7) 80.2 (69.0, 89.2)
Ixekizumab 80mg Q4W 3.7 (2.6, 5.3) 8.9 (5.7, 13.1) 48.8 (29.4, 68.6) 81.7 (71.7, 90.7)
Secukinumab 150mg QM 5.5 (4.1, 7.1) 11.0 (7.7, 15.3) 21.5 (8.86, 37.7) 69.2 (57.0, 79.5)
IL-12/23 inhibitor
Briakinumabb 100mg Q4W 5.8 (4.7, 7.0) 10.9 (8.8, 13.6) 19.0 (7.13, 34.8) 78.4 (67.2, 87.9)
Ustekinumab 45mg Q12W 7.1 (5.8, 8.7) 13.3 (11.1, 16.7) 10.2 (3.01, 21.6) 65.2 (51.9, 76.4)
Dihydrofolate reductase inhibitor
Methotrexate 18mg QW 9.2 (7.3, 11.5) 18.7 (15.3, 21.6) 3.38 (0.000, 8.61) 28.5 (17.0, 40.0)
JAK inhibitor
Tofacitiniba 5mg BID 6.9 (5.0, 9.6) 14.3 (9.4, 20.1) 9.21 (1.85, 19.4) 40.8 (28.2, 52.5)
Tofacitiniba 10mg BID 6.0 (4.5, 8.1) 12.2 (8.4, 17.5) 16.9 (6.23, 32.8) 60.7 (48.1, 72.5)
Baricitiniba 10mg QD NA NA NA NA
Vitamin A analog
Acitretin 30mg QD NA NA NA NA
CD2 antagonist
Alefacept 10mg QW 11.1 (9.0, 13.9) >24c (23.5, NA) 1.99 (0.000, 6.20) 15.6 (7.09, 24.1)
PDE4 inhibitor
Apremilast 30mg BID 7.4 (5.4, 10.2) 15.1 (10.2, 20.7) 5.66 (0.345, 12.7) 28.5 (17.9, 39.8)
Calcineurin inhibitor
Ciclosporin 2.5–5mg/kg/d NA NA NA NA
Values presented are mean (90% confidence intervals) and were generated assuming a typical weight of 90 kg.
aInvestigational. bDiscontinued. All other drugs are approved. cAlefacept data only reported up to 24 weeks; ET90 is estimated to occur sometime beyond the time period
for which there were reported data. BID, twice daily; BIW, twice weekly; CD2, T lymphocyte; ET50, time to reach 50% of the maximal treatment effect; ET90, time to reach
90% of the maximal treatment effect; IL, interleukin; JAK, Janus kinase; NA, not available; PASI75,75% reduction from baseline Psoriasis Area and Severity Index score;
PDE4, phosphodiesterase 4; QD, once daily; QM, once monthly; QW, once weekly; Q2W, once every 2 weeks; Q4W, once every 4 weeks; Q8W, once every 8 weeks; Q12W,
once every 12 weeks; TNF, tumor necrosis factor.
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response relationship for the model-predicted PASI response
overlaid with the observed data for each drug is presented in
Figure 3.
The model-predicted PASI responses for a typical patient for
each drug are summarized in Table 2. There was close agreement
between the estimates from the longitudinal model and the land-
mark model, although the conﬁdence intervals were generally
wider for the values generated from the longitudinal model.
The effect of body weight on PASI response was also tested in
the landmark model on placebo effect and/or drug effect terms.
There was no signiﬁcant improvement in the model ﬁt when
the weight effect was applied to any of the drug effect terms
(Emax, ED50), while it was signiﬁcant for the placebo effect term.
Therefore, the presented predictions are based on a model in which
body weight was retained for the placebo effect term alone.
Although the effect was small, weight was shown to have a statisti-
cally signiﬁcant negative effect on the placebo response (i.e., heavier
patients showed a lesser response compared with lighter patients).
Among injectable/infusible agents, IL-17 inhibitors were the
most efﬁcacious, with ixekizumab (80mg) demonstrating the
highest placebo-adjusted response rate (88.2% [86.8, 89.5] and
71.7% [69.1, 74.6] for PASI75 and PASI90, respectively) at
Week 12. Within the oral systemic treatments, tofacitinib 10mg
b.i.d. and cyclosporine 5mg/kg/d had comparable response rates
Figure 3 Landmark analysis of dose–response at 12 weeks in patients with moderate to severe psoriasis. Solid lines: model-predicted PASI endpoint
data at 12 weeks (not placebo-adjusted). The PASI responses at dose50 represent the placebo arm in each study. Circles represent observed data, with
size proportional to the N of patients in the study arm. CD2, T lymphocyte; IL, interleukin; JAK, Janus kinase; PASI50/75/90/100,50%,75%,90%,
or 100% reduction from baseline Psoriasis Area and Severity Index score; PDE4, phosphodiesterase 4; TNF, tumor necrosis factor. [Color figure can be
viewed at cpt-journal.com]
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of 53.8% (47.0, 58.7) and 46.7% (36.9, 56.5) for PASI75 and
27.5% (22.1, 31.8) and 22.1% (16.0, 29.6) for PASI90, respec-
tively. Acitretin 30mg q.d. and apremilast 30mg b.i.d. showed
the lowest efﬁcacy among the oral systemic agents (25.0% [16.1,
36.7] and 26.8% [23.2, 31.8] for PASI75, and 9.57% [5.55, 15.7]
and 10.3% [8.52, 12.8] for PASI90, respectively).
External validation (predicting longitudinal PASI90)
The ﬁnal longitudinal model, developed from the time-course
PASI75 dataset (test dataset), was used to predict the time-course
of PASI90 response (validation dataset). When scaling factors
obtained from the landmark model were incorporated into the
longitudinal model, predictions of PASI response were consistent
with the observed data, with the majority of reported PASI90
responses falling within the 90% prediction interval (Figure 5).
The central tendency of predicted PASI90 response appeared to
be slightly underestimated with brodalumab; however, all other
drugs were within the range of longitudinal prediction curves.
Based on Figure 2 and Figure 3, both models independently
showed good agreement between the observed and predicted data
Table 2 Landmark model-predicted percentage of PASI75 and PASI90 responders for systemic treatments in patients with
moderate to severe psoriasis at 12 weeks
Drug Clinical dose
Landmark model-predicted PASI
responders (%)
Landmark model-predicted difference
from placebo (%)
PASI75 PASI90 PASI75 PASI90
TNF-a inhibitor
Adalimumab 40mg Q2W 64.9 (59.9, 69.3) 37.9 (32.9, 42.9) 59.5 (54.5, 63.8) 36.3 (31.1, 41.2)
Certolizumaba 200mg Q2W 73.5 (55.1, 83.2) 48.2 (28.6, 62.7) 68.0 (49.7, 77.7) 46.5 (26.9, 60.8)
Etanercept 25mg BIW 37.4 (34.3, 41.1) 16.1 (14.1, 18.2) 31.9 (28.8, 35.7) 14.3 (12.4, 16.6)
Etanercept 50mg BIW 54.0 (51.3, 56.7) 27.6 (25.4, 30.1) 48.4 (45.8, 51.5) 26.0 (23.7, 28.4)
Infliximab 5mg/kg Q8W 77.0 (72.2, 80.7) 53.0 (46.1, 58.4) 71.6 (66.6, 75.1) 51.3 (44.4, 56.8)
IL-17 inhibitor
Brodalumaba 210mg Q2W 81.2 (77.0, 84.4) 59.3 (52.4, 64.4) 75.8 (71.5, 79.0) 57.7 (50.7, 62.9)
Ixekizumab 80mg Q4W 88.2 (86.8, 89.5) 71.7 (69.1, 74.6) 82.7 (81.2, 84.1) 70.0 (67.2, 72.9)
Secukinumab 150mg QM 75.7 (73.0, 78.4) 51.1 (47.2, 55.2) 70.2 (67.5, 73.1) 49.4 (45.6, 53.4)
IL-12/23 inhibitor
Briakinumabb 100mg Q4W 80.8 (78.4, 82.6) 58.4 (54.9, 61.9) 75.2 (72.9, 77.3) 56.8 (53.3, 60.4)
Ustekinumab 45mg Q12W 70.3 (67.8, 72.6) 43.6 (40.8, 46.7) 64.9 (62.3, 67.3) 41.9 (39.0, 45.1)
Dihydrofolate reductase inhibitor
Methotrexate 18mg QW 36.4 (32.7, 40.6) 15.5 (13.2, 18.1) 31.0 (27.2, 35.4) 13.8 (11.5, 16.3)
JAK inhibitor
Tofacitiniba 5mg BID 35.2 (30.9, 39.1) 14.8 (12.4, 17.1) 29.7 (25.2, 33.7) 13.1 (10.7, 15.5)
Tofacitiniba 10mg BID 53.8 (47.0, 58.7) 27.5 (22.1, 31.8) 48.2 (41.7, 53.2) 25.8 (20.7, 30.1)
Baricitiniba 10mg QD 33.2 (21.4, 49.0) 13.6 (8.05, 23.7) 27.5 (15.7, 43.9) 11.9 (6.28, 22.1)
Vitamin A analog
Acitretin 30mg QD 25.0 (16.1, 36.7) 9.57 (5.55, 15.7) 19.6 (10.6, 31.5) 7.92 (3.80, 14.1)
CD2 antagonist
Alefacept 10mg QW 22.7 (15.0, 30.3) 8.39 (5.23, 12.3) 17.2 (9.54, 24.9) 6.61 (3.53, 10.5)
PDE4 inhibitor
Apremilast 30mg BID 26.8 (23.2, 31.8) 10.3 (8.52, 12.8) 21.3 (17.6, 26.1) 8.60 (6.78, 11.1)
Calcineurin inhibitor
Ciclosporin 2.5–5mg/kg/d 46.7 (36.9, 56.5) 22.1 (16.0, 29.6) 41.2 (31.6, 50.8) 20.4 (14.3, 27.8)
Values presented are mean (90% confidence intervals) and were generated assuming a typical weight of 90 kg.
aInvestigational. bDiscontinued. All other drugs are approved. BID, twice daily; BIW, twice weekly; CD2, T lymphocyte; IL, interleukin; JAK, Janus kinase; PASI75/90,75%
or90% reduction from baseline Psoriasis Area and Severity Index score; PDE4, phosphodiesterase 4; QD, once daily; QM, once monthly; QW, once weekly; Q2W, once
every 2 weeks; Q4W, once every 4 weeks; Q8W, once every 8 weeks; Q12W, once every 12 weeks; TNF, tumor necrosis factor.
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for these compounds, conﬁrming that the models were reason-
ably describing the data.
DISCUSSION
Aggregate level landmark and longitudinal models were used to
evaluate the dose–response (magnitude) and time-course (onset
of drug effect) of PASI response in patients receiving systemic
agents for the treatment of moderate to severe psoriasis. Both
models adequately described the data, suggesting that the dose–
response relationships are well-captured using sigmoidal Emax
function structures, and that the maximum drug effect is
achieved within 12 weeks across most of the drugs included in
this analysis. Moreover, both models suggest that drugs with the
same mechanism of action demonstrate a consistent dose–
response.
One of the beneﬁts of the longitudinal model is that it enables
the comparison of the rate of onset among drugs. In this analysis,
ET50 was estimated from the predicted time-course of PASI75
responses. Generally, drugs with the highest efﬁcacy had the fast-
est onset of action. For example, the highest efﬁcacy was observed
with the IL-17 inhibitors ixekizumab and brodalumab (PASI75
response 80%) at the primary evaluation timepoint (12 weeks),
with ET50 of 3.7 and 3.9 weeks, respectively. In comparison, the
lowest efﬁcacy was observed for alefacept (PASI75 response 16%)
with an ET50 of 11 weeks. The average ET50 across all drugs in
this analysis was 6.5 weeks. Understanding differences in ET50
allows studies to be modiﬁed to provide an appropriate time-
frame to compare drug efﬁcacy. Early assessments (after 4–6
weeks of treatment) may be sufﬁcient for drugs with shorter
ET50 and highly efﬁcacious drugs (e.g., ixekizumab and brodalu-
mab), whereas a longer sampling duration may be required to
allow patients to achieve maximum beneﬁt for drugs with longer
ET50 (e.g., etanercept, methotrexate, or apremilast).
The relationship between body weight and PASI response
was of clinical interest, and an inverse relationship was detected
in this meta-analysis. In both longitudinal and landmark analy-
ses, body weight was identiﬁed as exhibiting an inverse effect on
Figure 4 Comparison of placebo-adjusted treatment effect (model predicted) for systemic psoriasis treatments: landmark analysis. Point estimates and
90% confidence intervals are predicted from model simulations (N51,000) for each drug, assuming a typical body weight of 90 kg. The recommended
dosage for ustekinumab is based on body weight (45mg ustekinumab for100 kg or 90mg ustekinumab for>100 kg). Therefore, the simulation
(N5500 for each body weight strata) for ustekinumab was conducted by body weight 100 kg and >100 kg, in which different doses (45mg or 90mg)
were assigned before calculating ustekinumab weighted average PASI responses. b.i.d., twice daily; b.i.w., twice weekly; CI, confidence interval; PASI50/
75/90/100,50%,75%,90%, or 100% reduction from baseline Psoriasis Area and Severity Index score; q.d., once daily; q.w., once weekly; q2w,
once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks. [Color figure can be viewed at cpt-journal.com]
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the placebo component of the model, suggesting that body
weight affects the overall PASI response regardless of drug. The
body weight effect was also signiﬁcant on the temporal compo-
nent of drug effect (kdrug) in the longitudinal model. These data
suggest that heavier patients tend to achieve lower efﬁcacy and
may also experience slower onset of effect compared with lighter
patients. The signiﬁcance of the weight effect on the placebo
components of the models should not be interpreted in a mech-
anistic context, as the models were developed based on summary
level, and not patient level, data. The important ﬁnding was
that, despite this attribution, body weight demonstrated an
effect on the absolute difference in the percentage of responders
between active and control groups. Therefore, increasing drug
dose may be particularly beneﬁcial for heavier patients if they
fail to show a meaningful clinical response at lower doses. Such
a decision to escalate the dose in heavier patients can be
achieved by evaluating the dose–response characteristics of each
drug and assessing the location of the clinical dose relative to
the drug’s ED50.
However, caution is required in interpreting covariate effects
with aggregate-level data. In general, meta-analyses using data
from the literature report covariates (age, body weight, sex, race,
etc.) as summary statistics (mean or median % of the trial data-
set), which results in reduced power to detect clinically relevant
interactions. In an analysis conducted by Lambert et al.,6 it was
demonstrated that even moderately strong interactions may not
be adequately detected in the meta-analytic setting. Furthermore,
there is also a risk that introduction of aggregate-level covariates
may result in underestimation of exposure–response effects.7
Therefore, although both meta-analytic models reported here
suggested that increasing body weight has an inverse effect on
PASI response, the true magnitude of this interaction may not
have been captured in this setting. Instead, the use of individual
level data may provide better estimates of the magnitude of this
effect and may enhance the understanding of this relationship on
a mechanistic level.
As with any meta-analysis, the utility of the results depends, in
part, on the studies that provided the information for analysis.
We therefore investigated heterogeneity in the aggregated pooled
dataset. During study selection, only predeﬁned inclusion and
exclusion criteria were applied to control for possible heterogene-
ity across the pooled studies. The parameterization of the
Figure 5 External validation of predicted PASI90 response over time. PASI90 time-course response was predicted using the final longitudinal model
(developed for PASI75) by incorporating parameter estimates (scaling factors between PASI75 and PASI90) from the landmark model on the placebo and
drug term. Solid line: predicted PASI90 response; gray shaded area: 90% confidence intervals; dotted lines: 95% confidence intervals; open circles:
reported PASI90 response. Doses are in mg, with the exception of infliximab (mg/kg). PASI75/90,75% or90% reduction from baseline Psoriasis
Area and Severity Index score. [Color figure can be viewed at cpt-journal.com]
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landmark model therefore incorporated a study-speciﬁc placebo
effect (E0) for each trial. In this manner, study-related differences
were accounted for by allowing the placebo effect of the PASI
response to shift across different studies. In contrast, the drug
effect was assumed to be constant across studies, i.e., all of the dif-
ferences in response for a given drug at a given dose were assumed
to be related to differences between studies and not to the drug
itself.
When predicted placebo effects (E0) from the landmark model
were plotted for each study (N5 71), they were shown to be nor-
mally distributed around a single value (data not shown). How-
ever, the I2 statistic8 of placebo effects (which describes the
percentage of variance that is related to between-study differ-
ences) was estimated to be 82%, suggesting that the parameteriza-
tion for study-speciﬁc placebo effect in the landmark model may
have helped to adequately control for any potential study-related
heterogeneity in the dataset. A similar approach (estimating
study-speciﬁc placebo effects) was also attempted in the longitu-
dinal model, but the results were inconclusive due to overparame-
terization. Instead, a placebo component was modeled as a
population mean response with between-study variability as a
random effect. The estimated random effects in the longitudinal
model were nearly normally distributed, suggesting that the parsi-
monious model (without estimating study-speciﬁc placebo
effects) is a reasonable alternative to describe the data.
Due to the advancement of antipsoriatic therapies, PASI90
may eventually replace PASI75 as the key indicator of efﬁcacy in
investigational trials.9 New psoriasis therapies with targeted
mechanisms (e.g., secukinumab, ixekizumab, and brodalumab)
have shown much higher levels of improvement in clinical stud-
ies, and therefore the emphasis from clinicians, regulators, and
drug developers is shifting to higher threshold endpoints, such as
PASI90. The external validation of predicted PASI90 response in
the longitudinal setting shows high agreement with the scalability
employed in the landmark setting, and both PASI75 and PASI90
results tended to plateau at 12 weeks. This suggests that a sim-
ple scaling factor can be used to link PASI75 and responses, espe-
cially in the period following attainment of Emax. It is worth
noting that the external validation was performed by bridging the
models, i.e., the longitudinal model for PASI75 was used to pre-
dict PASI90 by incorporating the estimated relationship between
PASI75 and PASI90 from the landmark model. This represents a
much higher hurdle for model validation than applying the same
model on a different dataset.
The magnitude of treatment effects for systemic agents was
visualized with predicted PASI responses. Consistent with previ-
ous reports,10 IL-17 inhibitors appeared to be the most efﬁca-
cious injectable/infusible psoriasis treatments, followed by other
classes of drugs. Inﬂiximab (5mg/kg) and ixekizumab (80mg)
had the highest responses among TNF-a inhibitors and IL-17
inhibitors, respectively. Among the oral agents, tofacitinib 10mg
b.i.d. and cyclosporine 5mg/kg/d appeared to have comparable
efﬁcacy, which was higher than other approved or investigational
systemic oral treatments. Acitretin 30mg q.d. and apremilast
30mg b.i.d. showed the lowest efﬁcacy among the oral systemic
treatments.
In summary, two mathematical models were developed to
describe the time-course and dose–response from the data across
all systemic treatments for patients with psoriasis. The simulation
results also suggest that the model could be useful to predict the
time-course of other PASI subscales such as PASI90. These mod-
els provide a quantitative framework to understand the current
treatment options and a potential use of models in drug develop-
ment, either alone or bridging together, to predict the time-
course for endpoints of interest with investigational drugs.
METHODS
Database development
The data for the analysis originated from two sources: data from the lit-
erature for approved and investigational psoriasis treatments from 1998
through 2015, and summary level data for tofacitinib phase II and III
clinical studies. Although the results from tofacitinib clinical studies are
published, the corresponding summary data for this analysis were
obtained from a Pﬁzer internal database to maintain numerical accuracy.
Literature search and data selection. Following the search and selec-
tion strategy proposed by the Cochrane group,11 the Ovid Medline search
engine, US-based and European regulatory documents such as Summary
Basis of Approvals and European Public Assessment Reports were
searched from 1964 to 2015 for reports of PASI responders in clinical tri-
als for the pharmaceutical treatment of psoriasis. The search strategy
focused on moderate to severe plaque psoriasis, randomized placebo- or
active-controlled trials of IL-12/23 inhibitors, TNF-a inhibitors, IL-17
inhibitors, CD2 antagonists, PDE4 inhibitors, JAK inhibitors, and tradi-
tional oral agents. The primary efﬁcacy endpoint PASI75 and other PASI
scores (PASI50, PASI90, and PASI100) were captured in the database.
Abstracts of potential records were screened by qualiﬁed personnel to
determine the relevance to the research objectives; the study designs, treat-
ment regimens, and patient populations were scrutinized to ensure that all
studies represented data that supported pooling. PASI response data that
passed the screening process were extracted from published articles, rele-
vant conference posters, and/or abstracts. The data from selected sources
were captured or digitized, then data curation (e.g., unit standardization,
normalization of different dose regimen) was performed.
Although a single database was generated to support both the longitu-
dinal and landmark analysis, three separate datasets were created as
required by the modeling objectives. In the longitudinal analysis, all
repeated measures of PASI75 response (test dataset) were used for model
building, and all repeated measures of PASI90 response (validation data-
set) were used for the external validation. The third dataset was for the
landmark analysis; PASI responses (PASI50, 75, 90, 100) at the primary
efﬁcacy measurement time (majority of studies were 12 weeks; range,
10–24 weeks) were included.
Model development
Longitudinal model. The longitudinal model structure consisted of pla-
cebo and drug effects that were exponential vs, time describing the longi-
tudinal aspect of the effect. The response value was transformed into the
logit scale to restrict the estimated probability values between 0 and 1 as
shown in the following equations:
PrðPASI75Þ5gff01fdrugg (1)
g5
1
11e2ðf01fdrug Þ
(2)
f05A1B 

12e2kpbotimeexpðhÞ

(3)
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fdrug5
Emaxdrug  ð12e2kdrug timeÞ  Doseg
Doseg1EDg50;drug
(4)
where Pr is the probability, g is the inverse logit function to transform
the treatment effect, which is the sum of placebo (f0) and drug effect
(fdrug) to the probability scale. The parameter kpbo and kdrug are rate con-
stants describing onset of placebo and drug effects, respectively, with a
modeled unique estimate for each drug.
The dose–response component of the model was described by a sig-
moidal Emax function. The model estimated the parameters for A (inter-
cept), B (asymptote on placebo model), E (asymptote on drug model),
ED50 (dose achieving 50% of maximal response), for each drug. The nor-
malized dose by the regulatory approved dose regimen, or normalized
dose by the most frequently reported dose regimen (for nonapproved
drugs) was used to account for different doses or unique titration
schemes for each drug during clinical studies. The Hill coefﬁcient (c)
was also tested in the model. However, the parameter(s) were not esti-
mated for rate constant or dose–response terms if there was not sufﬁ-
cient longitudinal or dose–response information available for a certain
drug. The between-study variability was described by g, having a normal
probability distribution with mean 0 and variance x2.
Landmark model. A joint analysis of the efﬁcacy endpoints (PASI50,
75, 90, and 100) was performed to estimate differences in relative effect
for each endpoint by treatment. The response variable was the percent-
age of patients achieving PASI50, 75, 90, and 100 at each trial endpoint,
typically 12 weeks postﬁrst-dose administration.
The structure for the joint meta-regression model of PASI50,
PASI75, PASI90, and PASI100 responses is summarized in Equations 5
through 8. The ﬁnal model was structured as follows:
PðeventÞijk5gfEoi1Edrug1hi;kg (5)
where PðeventÞijk represents the probability (%) of a patient having an
event for the kth endpoint in the jth treatment arm of the ith trial and g
was the inverse logit function to transform the treatment effect to the
probability scale.
Eoi captures the estimated placebo response in PASI75 scores for a
patient with body weight 90 kg (approximate median of the dataset) in
the ith trial as deﬁned in Equation 6. A different placebo response was
estimated for every trial with a constant ﬁxed shift between PASI
levels.
Eoi5triali1PASI50  I11PASI90  I21PASI100  I3 (6)
where triali is a baseline placebo effect for the i
th trial; I1, I2 and I3 are
coefﬁcients for PASI50, PASI90, or PASI100 relative to PASI75
scores.
Edrug represents the drug-response with drug-speciﬁc model parame-
ters, such as maximum response for each drug (emd) and an effective
dose for each individual drug (ED50,d). For the traditional oral systemic
treatments (methotrexate, cyclosporine, and acitretin), the optimal PASI
responses were achieved in practice by ﬂexible dose adjustment for each
patient, based on safety and efﬁcacy. Therefore, there were insufﬁcient
data in the literature to fully describe the dose–response relationship for
these drugs. As such, the maximum responses for traditional oral sys-
temic agents were modeled as single-step offsets (Equation 7).
For TNF-a inhibitor, IL-12/23 inhibitor, IL-17 inhibitor, CD2
antagonist, PDE4 inhibitor, and JAK inhibitor, a sigmoidal Emax func-
tion was used to describe the relationship between dose and PASI
response for each drug (Equation 7). As with E0, a scaling factor was
applied to the estimated Emax to account for differences in PASI75,
PASI50, PASI90, and PASI100 scores (Equation 8).
If drug is traditional systemic agent : em5emd ;
All other drugs : em5
emd  DOSEgdd
expðED50;dÞgd1DOSEgdd
(7)
Edrug5em  ð11PASI50  I51PASI90  I61PASI100  I7Þ (8)
In the above equations, emd represented the drug-speciﬁc maximum
effect; cd was the Hill coefﬁcient; ED50,d was the estimated dose of half
of the maximum effect and I5, I6, and I7 were scaling factors applied to
PASI50, PASI90, and PASI100 scores, respectively. In this analysis, a sin-
gle Hill coefﬁcient was applied to all drug classes except for IL-17 inhibi-
tors. The dose–response curve for IL-17 inhibitors was sufﬁciently
different from other drugs of interest that an individual offset was
required to more appropriately describe the dose–response relationship.
The random effect gi,k on overall drug response (E01Edrug) was deﬁned
as having a mean 0 and variance x2k. The model included terms to account
for the correlation between different PASI scores (i.e., PASI50, PASI75,
PASI90, or PASI100) within the same study and to account for the correla-
tion between PASI scores among different arms within the same study.
Covariate model. Based on previous knowledge,12,13 body weight was
an important determinant of efﬁcacy in patients with psoriasis. There-
fore, body weight was tested as a covariate in the longitudinal model and
in the landmark model if body weight data were available in the litera-
ture (aggregated level, either by study arm or stratiﬁed by body weight),
as described in Equations 9 and 10, respectively:
WTeffect5
WEIG
90
 u
(9)
WTeffect5ðWEIG290Þ  I4 (10)
If body weight data were not reported (10–15% of studies in the liter-
ature), WEIG was set to 90 so that there was no inﬂuence on the
covariate estimation. The weight effect was tested on the treatment
effect of the drug (Emax, ED50, or kdrug), as well as on the placebo
effect (E0).
Residual error model. In both the longitudinal and landmark analyses,
the predicted PASI responses represented the probability of 50,  75,
 90, or 100% improvement in PASI scores. The residual error compo-
nent (E) had a normal probability distribution with mean 0 and variance
r2. Weight based on standard errors of ﬁtted values (see Equations 11
and 12) was noted as W, and the number of subjects for each arm
within each study to account for the effect on parameter estimation due
to the size of each trial was noted as N. Because studies were weighted
by inverse of standard errors, larger studies had more inﬂuence on esti-
mating the parameter means.
PASI responsef50;75;90;100gð%Þ5PrðPASIf50; 75; 90; 100gÞ1W  e
(11)
W5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Prð12PrÞ
N
r
(12)
Additionally, due to the longitudinal nature of the data and correlation
within timepoint measurements of the same group of patients,14 a third
level of variability (with mean 0 and variance r2CORR) was also incorpo-
rated into the longitudinal model as shown below:
PASI755PrðPASI75Þ1W  ðe1ecorrÞ (13)
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The standard model diagnostics (e.g., goodness-of-ﬁt plots, precisions
of the parameter estimates) were performed for both models to assess the
model adequacy and any residual error model misspeciﬁcations.
Simulations. Simulations were performed using the ﬁnal model param-
eter estimates. The results were overlaid with observed data for both
time course (longitudinal) and dose–response at 12 weeks (landmark)
data by drug (and by dose) to visually compare the results and conﬁrm
the model performance. Predicted PASI75 responses generated from the
longitudinal model were compared to predicted PASI75 responses from
the landmark model to demonstrate consistency between the models.
ET50 and ET90 (the time to reach 50% and 90% of the maximal treat-
ment effect) were also calculated from the longitudinal model.
The ﬁnal landmark model was used to simulate PASI75 or PASI90
responses at Week 12 for a typical patient with moderate to severe psoria-
sis for each drug at clinically recommended doses. Placebo-adjusted treat-
ment effect (effect size) for each drug was summarized in a forest plot.
External validation. External validation was performed for PASI90
time-course response (using the validation dataset), in which the ﬁnal
model for longitudinal PASI75 was used to simulate (N5 1,000) the
PASI90 time-course by incorporating the scaling factor between PASI75
and PASI90 obtained from the landmark model, then overlaid with the
observed PASI90 time-course data.
Modeling software. Longitudinal data analyses were conducted using
Nonlinear Mixed Effect Modeling software NONMEM (v. 7.3) using the
ﬁrst-order conditional expectation method. A nonlinear mixed-effects rou-
tine in S-PLUS 8.0.4 for Windows (Insightful, Seattle, WA) was used for
the landmark analysis. The input datasets and model outputs were manip-
ulated and all graphical displays were generated using R (v. 3.0.2) and
Rstudio (v. 0.99.879). Bootstrap was performed using PsN (v. 3.5.4).
Additional Supporting Information may be found in the online version of
this article.
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